Oct 2022 – Present · 3 yrs 5 mos

• Leading the Oncology / Hematology team for France (Medical, Commercial, Diagnostics, Innovation), across 6 therapeutic areas (Lung, Breast, Gyn, GU, GI and Hem)
• Fostering a culture of growth, development and impact for the 270 + people in my organization, focusing on improving patient care and supporting equitable access to innovation
• Accompanying the evolution of the organization to deliver in a sustainable and scalable manner the next wave of innovation (40+ read out across 10+ molecules in the next 3-4 years)

Dec 2020 – Oct 2022 · 1 yr 10 mos

Oct 2019 – Dec 2020 · 1 yr 2 mos

•  Collaboration with R&D, Regulatory, Clinical, Strategy teams in the generation and design of new Ph2/3 studies
•  Leading potential protocol updates between study sign-in and DCO
•  Coordination of Global pre-launch cross-functional activities (Brand Strategic Plan), for studies closer to launch, including supervising country launch readiness

Jul 2019 – Sep 2019 · 2 mos

• Coordinated financial and strategical exercises (Q2 quarterly business review, long term forecasting exercises AZ and AZ/MSD, brand strategic plans) and managed the Alliance with Merck at European level (EU5 + smaller EU countries)

Nov 2017 – Oct 2019 · 1 yr 11 mos

• FULL ACCOUNTABILITY OF FRANCHISE P&L
•  Established portfolio strategy
•  Set financial targets (topline and bottom-line) & defended them with S.E.T. Direct management of bus. analyst
•  Led commercial operations according to plans and put in place corrective actions when relevant
•  Managed resources allocation between products and indications
• DIRECTOR OF SALES
•  Managed and developed 4 First Line sales Managers, in charge of 22 reps
•  Launched several indications (2 for Faslodex®, 3 for Lynparza®), relaunched Zoladex® (mature product) and managed end of promotion of Faslodex®
•  Drove salesforce capabilities development (strategic account management, scientific leadership, leadership selling, new channels…)
•  Ensured field execution (incentive strategy, segmentation & targeting, multi-channel plans)
• FRANCHISE STRATEGY
•  Influenced Lynparza® global strategy as member of the Global Brand Team
•  Developed marketing team autonomy to deliver best-in-class HCP and patient oriented marketing campaigns
•  Built from scratch understanding of new markets (prostate cancer, pancreatic cancer)
•  Developed partnerships with key medical experts and scientific societies
• AZ-MSD ALLIANCE MANAGER
•  Delivered local implementation of global co-promotion deaf with MSD: from contract drafting to field collaboration execution

Nov 2016 – Oct 2017 · 11 mos

• Business portfolio: Lynparza® in Ovarian Cancer (launched) and Breast Cancer (pre-launch) and Faslodex® in metastatic Breast Cancer (2 new indications launched H2 2017)
• STRATEGIC BRAND PLANNING
• Clarified and reprioritized Lynparza® strategy
• Dealt in depth with Faslodex® patient segment prioritization and accounts / HCP segmentation & targeting
• Supervising 2018 Brand Planning process with Brand Managers and Market Research Analysts
• WOMEN’S PORTFOLIO OPERATIONAL EXECUTION
• Leading the Womens’ Cancer cross-functional Core Team: empowering team members to put in place and follow-up action plans to ensure sales targets are met
• Closely collaborating with SLSM and Training to ensure on-boarding of new salesforce team post “PSE”
• Developing partnerships with key medical experts and scientific societies
• ONCOLOGY & ENTERPRISE PROJECTS
• Leading the creation and deployment of a 360° CRM for KEE activities follow-up
• Participating to “Differentiated Hospital Business Model” enterprise project
• Led the design and animation of the 2017 Affiliate Managers’ Campus (>70 field and HQ managers)

Mar 2015 – Dec 2016 · 1 yr 9 mos

• Business portfolio : Diabetes (oral DPP4i, ~30m€, launched in sept. 2010 / injectable GLP1a: ~ 30m€ launched in June 2015 / oral SGLT2i: to be launched)
• + ZS9 in hyperkalemia (assessment for French market on-going)
• Development and management of a team of 9
• Strategic Brand Planning for the diabetes portfolio, and full opportunity assessment for ZS9
• Coordinated the Brand Plan process for all brands of the portfolio
• Actively contributed to the market access strategies for Forxiga®
• Set top line objectives & ambition
• Diabetes portfolio operational execution
• Led the Diabetes cross-functional Core Team (marketing / medical / sales / market access / finance / SFE)
• Monitored the cross-functional plans’ implementation and execution through scorecard
• Put in place corrective actions when needed
• Developed strong partnerships with key medical experts
• Strongly impacted the Salesforce team both HQ and field (250 people)
• RESPONSIBILITIES SIMILAR TO WOMEN’S CANCER GROUP MANAGER ROLE
• Key achievements:
•  Bydureon® launch in France: highest uptake worldwide in DoT market share
•  Active participation in Forxiga® market access strategies, including strategic scenario planning
•  Strong impact on Salesforce team both HQ and field (250 people)
•  Maintained a high level of team members’ engagement in an uncertain external & internal environment
•  Managed underperformance in my team and recruitment of talent
•  Actively participated to the deployment of “Individual Development” culture within the affiliate (HQ and field), through IDP training campaign, feedback campaign and design of the Development Week content

Aug 2014 – Mar 2015 · 7 mos

• Overhauled local brand strategy : brand positioning, prioritized opportunities, messaging and tactical plan
• Drove efficient implementation by brand manager and SF teams: coherence of sales campaigns and activities with new strategy
• Managed 1 brand manager, 1 assistant and 1 market research manager
• Developed strong partnerships with key medical experts and influencers